TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting

TG THERAPEUTICS, INC.

Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).
Shareholders approved amendment to 2022 Incentive Plan removing full-value award limit (66.7M for, 8.6M against).
Two director nominees (Yann Echelard, Daniel Hume) each received less than 50% of votes cast for election.
Advisory say-on-pay proposal passed with 55.6% support (42.3M for, 31.0M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.